Skip to content

Bronchial Inflammation in Patients With Bronchiolithis Obliterans

Lung Function and Bronchial Inflammation in Patients With Bronchiolithis Obliterans

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01633385
Acronym
FRABO-02
Enrollment
37
Registered
2012-07-04
Start date
2012-04-30
Completion date
2012-12-31
Last updated
2013-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiolitis Obliterans

Keywords

bronchial inflammation, Bronchiolitis obliterans, Sputum, Blood, Inflammation, adaptive immune system, innate immune system

Brief summary

The investigators plan to study the variability of lung function parameters and bronchial inflammatory markers in 20 patients with bronchiolitis obliterans at the age of 6 to 25 years compared with an age- and sex-matched control group. The investigators will perform a pulmonary function test (body plethysmography with TLCO), and measure the fraction of exhaled nitric oxide (eNO). Further a blood sample is drawn to determine the systemic inflammation. Finally induced sputum is collected and a cell count is performed, and cells and supernatants are analyzed for inflammatory markers. This investigation will be repeated after 4-6 weeks. The aim of this study is to define baseline values and the variability of possible outcome parameters for future interventional studies.

Detailed description

The purpose of this study is to characterize the variability of lung function values and bronchial inflammation of 20 Patients with Bronchiolitis obliterans aged between 6 up to 25 years. The patients' data will be compared with the results of a reference group with similar age conditions to determine possible outcome-parameters for following interventional studies. The sputum samples will be processed and quantitatively analyzed to get a profile of the cytological composition. (Sputum and serum samples are analyzed by quantitative real-time polymerase chain reaction (PCR) (qRT-PCR) and by cytometric bead assay (CBA).) Methods and Work Programme: This study consists of two study visits (V1 and V2) V1: * Measurement of nitric oxide in expired air (eNO) * Lung function testing with spirometry and body plethysmography * Bronchodilation * Lung function testing with spirometry and body plethysmography * Blood test: blood count, CRP, RAST, serum inflammatory mediators, (genetic markers of the non-specific pulmonary defense system) * Induced sputum for inflammatory mediators and microbiological investigations V2: * Measurement of nitric oxide in expired air (eNO) * Lung function testing with spirometry and body plethysmography * Bronchodilation * Lung function testing with spirometry and body plethysmography * Induced sputum for inflammatory mediators and microbiological investigations

Interventions

None listed

Sponsors

Johann Wolfgang Goethe University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
6 Years to 25 Years
Healthy volunteers
Yes

Inclusion criteria

* informed consent * between 6 and 25 years of age * Known Bronchiolitis obliterans * no Bronchiolitis obliterans(depending on the study group) * Ability to perform lung function tests and inhalation

Exclusion criteria

* Acute illness with systemic or bronchial inflammation * every chronic condition or infection (eg HIV, tuberculosis, malignancy) * pregnancy * known alcohol and/ or drug abuse * Inability to understand the extent and scope of the study * Participation in another study

Design outcomes

Primary

MeasureTime frameDescription
Change of FEF75 over timeV1: Day 1 - V2: Day 28-42Look for changes/ variability of this lung function parameter

Secondary

MeasureTime frameDescription
change of sputum cell count over timeV1: Day 1 - V2: Day 28-42induced sputum will be analyzed for different cellular components such as alveolar macrophages, neutrophils, lymphocytes and others. Epithelial cells will be excluded
change of low CrP over timeV1: Day 1 - V2: Day 28-42serum parameter for systemic inflammation

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026